Law ❯ Legal Representation ❯ Contingency Fees
Investor Advocacy Rosen Law Firm Bernstein Liebhard LLP Investor Counsel Litigation Success
The pending Northern District of California case challenges disclosures about Cytokinetics’ aficamten review after an FDA‑requested REMS delayed the timeline.